Concepedia

Al-Ola Abdallah

AA

Statistics

Publications

4

Citations

96

H-Index

4

Active since

2020

Affiliations

The University of Kansas Cancer Center(Current)

National and Kapodistrian University of Athens

Canossa Private Hospital

GlaxoSmithKline (Canada)

First Affiliated Hospital of Soochow University

Al-Ola Abdallah is an author at The University of Kansas Cancer Center specializing in primary outcome analysis, immunotherapy, and multiple myeloma chemotherapy.

Publications per year

2020–2025

4

Publications

4

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

Paul G. Richardson, Hans C. Lee, Al-Ola Abdallah et al. · Blood Cancer Journal · 2020 · 56 citations · Full text

, , +13

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Vânia Hungria, Paweł Robak, Marek Hus et al. · The Lancet Oncology · 2025 · 16 citations

, , +11

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Vânia Hungria, Paweł Robak, Marek Hus et al. · Blood · 2024 · 14 citations

, , +17

Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Neil Dunavin, Lih-Wen Mau, Christa L. Meyer et al. · Biology of Blood and Marrow Transplantation · 2020 · 10 citations · Full text

, , +15

1–4 of 4